Reuters logo
MARKET EYE-Natco, Cipla up; India's top court dismisses Novartis petition
April 1, 2013 / 5:51 AM / 4 years ago

MARKET EYE-Natco, Cipla up; India's top court dismisses Novartis petition

* Shares in Natco Pharma Ltd and Cipla Ltd 
gain after India's highest court dismissed Swiss drugmaker
Novartis AG's petition seeking patent for its cancer
drug Glivec.
* In a landmark judgment that has the potential to change the
direction of India's pharmaceutical business, the Supreme Court
said on Monday that the drug failed to qualify for a patent
according to Indian law. 
* Analysts say that will be a big win for generic drugmakers
given huge difference in prices of monopoly drugs, and as other
emerging countries are also expected to follow India's top
court's decision.
* Cipla and Natco are already selling generic versions of Glivec
in India.
* Natco was up 4.2 percent, while Cipla rose 1.8 percent at 0532
GMT. 

 (abhishek.vishnoi@thomsonreuters.com /;
Kaustubh.Kulkarni@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below